ArticleInfection and drug resistance2025
Clinical Characteristics, Prognosis, and Risk Factors for Mortality in Influenza-Associated Pulmonary Aspergillosis and COVID-19-Associated Pulmonary Aspergillosis: A Multicenter Retrospective Study.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Machine learning for early screening of influenza A-associated invasive pulmonary aspergillosis in hospitalized patients: a real-world study.Frontiers in cellular and infection microbiology · 2026Article
- Interpretable machine learning identifies immune-inflammatory and immunothrombotic biomarkers for myocardial injury and mortality risk stratification in severe pneumonia with diverse infectious etiologies.Frontiers in cellular and infection microbiology · 2026Article
- Comparative clinical features and outcomes of invasive pulmonary aspergillosis following influenzaFrontiers in medicine · 2026Article
- Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Multiple studies have confirmed that viral pneumonia is a high-risk factor for invasive pulmonary aspergillosis (IPA), this retrospective study aims to analyze the differences in clinical characteristics, prognosis, and high-risk factors for mortality between patients with influenza virus-associated pulmonary aspergillosis (IAPA) and those with COVID-19-associated pulmonary aspergillosis (CAPA). Methods: Clinical data from IAPA and CAPA patients diagnosed at four hospitals were collected. The clinical characteristics and prognostic differences between the two groups were analyzed and compared, with Cox regression used to identify the risk factors for mortality. Results: A total of 106 patients were included in this study. Compared to CAPA patients, IAPA patients had a higher proportion of chronic obstructive pulmonary disease comorbidities, lower rates of history of solid organ transplantation, and a shorter time from viral infection to aspergillosis development. CAPA patients exhibited lower levels of white blood cells, and C-reactive protein. The CAPA group also received longer courses of antibiotic and corticosteroid therapy. Compared to IAPA, the CAPA group exhibited a higher incidence of complications, including bacterial infections, deep vein thrombosis in the lower limbs, gastrointestinal bleeding, and heart failure. The mortality rate was also higher in the CAPA group. The survival curve of IAPA was more favorable than that of CAPA. Cox regression analysis identified ICU admission at diagnosis as an independent risk factor for mortality in IAPA patients (OR= 9.578). Conclusion: The IAPA group had a higher proportion of patients with COPD, a more acute disease onset, Admission to the ICU at diagnosis was identified as a risk factor for IAPA-related mortality. In comparison, the CAPA group had a higher proportion of immunodeficient patients, received more corticosteroid treatment, and was more susceptible to complications such as bacterial infections, thrombosis, and gastrointestinal bleeding, all of which contributed to an increased risk of death.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.